ウロミューン
引用

1 2 3 4 5 6 7 8  “MV 140”. Adis Insight.   Springer Nature Switzerland AG. 15 February 2024閲覧。
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43  “An Effective Sublingual Vaccine, MV140, Safely Reduces Risk of Recurrent Urinary Tract Infection in Women”. Pathogens 12 (3):  359. (February 2023). doi:10.3390/pathogens12030359. PMC 10052183. PMID 36986281. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052183/.
1 2 3 4 5 6 7 8 9 10 11 12 13  “Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future”. Can Urol Assoc J 14 (8):  281–287. (August 2020). doi:10.5489/cuaj.6690. PMC 7402698. PMID 33626320. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402698/.
1 2 3 4  “Sublingual MV140 for Prevention of Recurrent Urinary Tract Infections”. NEJM Evid 1 (4):  EVIDoa2100018. (April 2022). doi:10.1056/EVIDoa2100018. PMID 38319200.
1 2 3 4 5 6 7 8 9 10 11 12 13 14  “Role of Vaccines for Recurrent Urinary Tract Infections: A Systematic Review”. Eur Urol Focus 6 (3):  593–604. (May 2020). doi:10.1016/j.euf.2019.11.002. PMID 31806578.
1 2 3 4 5 6 7 8  Hart, Janelle (September 16, 2021). Novel vaccine MV140 effective at treating recurrent UTIs. 49. https://www.urologytimes.com/view/novel-vaccine-mv140-effective-at-treating-recurrent-utis.
1 2 3  “A Focus on Long-Term Follow-Up of Immunoprophylaxis to Recurrent Urinary Tract Infections: 10 Years of Experience with MV140 Vaccine in a Cohort of 1003 Patients Support High Efficacy and Safety”. Arch Esp Urol 75 (9):  753–757. (November 2022). doi:10.56434/j.arch.esp.urol.20227509.110. PMID 36472057.
1 2  “MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL-10 responses via Syk and MyD88”. Mucosal Immunol 10 (4):  924–935. (July 2017). doi:10.1038/mi.2016.112. PMID 27966556.
1 2 3 4  “Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics”. Int Urogynecol J 24 (1):  127–34. (January 2013). doi:10.1007/s00192-012-1853-5. PMC 3536982. PMID 22806485. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536982/.
1 2 3  “Vaccine development for bacterial pathogens: Advances, challenges and prospects”. Trop Med Int Health 28 (4):  275–299. (April 2023). doi:10.1111/tmi.13865. PMID 36861882. "Uromune, developed by Inmunotek, a Spanish-based pharmaceutical company, is also currently in phase III clinical trial. This vaccine, Uromune, administered as a spray, has proven to be highly effective against chronic or recurrent UTIs. It contains inactivated E. coli, Proteus vulgaris, K. pneumoniae and Enterococcus faecalis (https://Clinicaltrials.gov)."
1 2 3 4 5 6 7 8 9  “Sublingual Vaccine Shows Efficacy in Preventing Recurrent UTIs, Helping to Eliminate Need for Antibiotics” (25 May 2023). 15 February 2024閲覧。
1 2 3 4  Nickel, J. Curtis; Lorenzo-Gómez, María Fernanda; Foley, Stephen; Saz-Leal, Paula (2021). “PLLBA-02 A novel sublingual vaccine will dramatically alter the clinical management of recurrent urinary tract infections in women”. Journal of Urology 206 (Supplement 3). doi:10.1097/JU.0000000000002150.02. ISSN 0022-5347.
↑  “Catheter-Associated Urinary Tract Infections: Current Challenges and Future Prospects”. Res Rep Urol 14:  109–133. (2022). doi:10.2147/RRU.S273663. PMC 8992741. PMID 35402319. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992741/. "MV-140 (Uromune, Syner-Med Ltd UK; Immunotek S.L. Spain), a sublingual spray, has been evaluated for safety and efficacy.128 The MV-140 vaccine is composed of inactivated cell lysates of common uropathogens. Specifically, it contains lysates of E. coli, Klebsiella pneumonia, Proteus vulgaris, and Enterococcus faecalis. In a prospective study that included 77 women with recurrent UTI (each had 3 or more UTI episodes in the preceding 12 months), the vaccine was administered for 3 months, and 78% of the population was UTI-free over the 12-month follow-up period.128 In this study, one patient experienced rash and thus had to stop treatment. The first phase III, randomized, placebo-controlled, double-blind clinical trial was recently reported.129 The trial included 240 women with recurrent UTI, randomized to either MV140 (for 3 or 6 months) or placebo. The median number of UTIs in the 9 months post-vaccination was 3.0 in the placebo compared to 0.0 in the MV-140 treatment groups. There was a greater UTI-free rate in the MV-140 groups. Five subjects reported adverse reactions, all of which were non-serious (3 in the treatment groups, 2 in the placebo group). While these remarkable findings open new prevention avenues for this patient cohort, whether or not they are generalizable to a population with indwelling urethral catheters remains to be determined."
1 2 3  “MV140 sublingual vaccine reduces recurrent urinary tract infection in women Results from the first North American clinical experience study”. Can Urol Assoc J 18 (2):  25–31. (February 2024). doi:10.5489/cuaj.8455. PMC 10841562. PMID 37931282. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10841562/.
1 2  “MV140 sublingual vaccine proves promising in fighting recurrent urinary tract infections in women”. Can Urol Assoc J 18 (2):  32. (February 2024). doi:10.5489/cuaj.8716. PMC 10841568. PMID 38315548. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10841568/.
1 2 3  "Vaccine for recurrent UTIs reduces infection rate by 74.8%", www.healio.com
↑  Kanabar, S.; Foley, S.; Yang, B. (2024). “Assessing the long-term efficacy and safety of MV140 sublingual bacterial vaccine in the initial cohort: A 9-year study in the UK for treating recurrent urinary tract infections in men and women”. European Urology 85 (Suppl 1):  S1037–S1037. doi:10.1016/S0302-2838(24)00833-9.
↑  “Evaluation of MV140 in preventing recurrent urinary tract infections: a multicentre double-blind randomized controlled trial protocol”. BJU Int. (December 2023). doi:10.1111/bju.16247. PMID 38060333.
↑  “A Combination of Polybacterial MV140 and Candida albicans V132 as a Potential Novel Trained Immunity-Based Vaccine for Genitourinary Tract Infections”. Front Immunol 11:  612269. (2020). doi:10.3389/fimmu.2020.612269. PMC 7858650. PMID 33552074. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858650/.
↑  “Candida albicans V132 induces trained immunity and enhances the responses triggered by the polybacterial vaccine MV140 for genitourinary tract infections”. Front Immunol 13:  1066383. (2022). doi:10.3389/fimmu.2022.1066383. PMC 9729253. PMID 36505433. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729253/.